PCI Biotech (Norway) Buy Hold or Sell Recommendation
| PCIB Stock | NOK 1.62 0.08 4.71% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding PCI Biotech Holding is 'Strong Sell'. Macroaxis provides PCI Biotech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PCIB positions. The advice algorithm takes into account all of PCI Biotech's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting PCI Biotech's buy or sell advice are summarized below:
Real Value 1.45 | Hype Value 1.62 | Market Value 1.62 | Naive Value 1.57 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell PCI Biotech Holding given historical horizon and risk tolerance towards PCI Biotech. When Macroaxis issues a 'buy' or 'sell' recommendation for PCI Biotech Holding, the advice is generated through an automated system that utilizes algorithms and statistical models.
PCI |
Execute PCI Biotech Buy or Sell Advice
The PCI recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on PCI Biotech Holding. Macroaxis does not own or have any residual interests in PCI Biotech Holding or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute PCI Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
PCI Biotech Trading Alerts and Improvement Suggestions
| PCI Biotech Holding generated a negative expected return over the last 90 days | |
| PCI Biotech Holding may become a speculative penny stock | |
| PCI Biotech Holding has high historical volatility and very poor performance | |
| The company reported the revenue of 6.27 M. Net Loss for the year was (88.39 M) with profit before overhead, payroll, taxes, and interest of 6.27 M. | |
| PCI Biotech Holding has accumulated about 116.12 M in cash with (68.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders |
PCI Biotech Returns Distribution Density
The distribution of PCI Biotech's historical returns is an attempt to chart the uncertainty of PCI Biotech's future price movements. The chart of the probability distribution of PCI Biotech daily returns describes the distribution of returns around its average expected value. We use PCI Biotech Holding price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of PCI Biotech returns is essential to provide solid investment advice for PCI Biotech.
| Mean Return | -0.36 | Value At Risk | -5.62 | Potential Upside | 5.33 | Standard Deviation | 3.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of PCI Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
PCI Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to PCI Biotech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that PCI Biotech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a PCI stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.36 | |
β | Beta against NYSE Composite | -0.22 | |
σ | Overall volatility | 3.36 | |
Ir | Information ratio | -0.13 |
PCI Biotech Volatility Alert
PCI Biotech Holding exhibits very low volatility with skewness of 0.19 and kurtosis of -0.29. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure PCI Biotech's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact PCI Biotech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.PCI Biotech Fundamentals Vs Peers
Comparing PCI Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze PCI Biotech's direct or indirect competition across all of the common fundamentals between PCI Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as PCI Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of PCI Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing PCI Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare PCI Biotech to competition |
| Fundamentals | PCI Biotech | Peer Average |
| Return On Equity | -0.74 | -0.31 |
| Return On Asset | -0.4 | -0.14 |
| Operating Margin | (15.29) % | (5.51) % |
| Current Valuation | 25.47 M | 16.62 B |
| Shares Outstanding | 37.33 M | 571.82 M |
| Shares Owned By Insiders | 31.97 % | 10.09 % |
| Shares Owned By Institutions | 6.90 % | 39.21 % |
| Price To Earning | (10.88) X | 28.72 X |
| Price To Book | 1.44 X | 9.51 X |
| Price To Sales | 18.74 X | 11.42 X |
| Revenue | 6.27 M | 9.43 B |
| Gross Profit | 6.27 M | 27.38 B |
| EBITDA | (85.76 M) | 3.9 B |
| Net Income | (88.39 M) | 570.98 M |
| Cash And Equivalents | 116.12 M | 2.7 B |
| Cash Per Share | 8.83 X | 5.01 X |
| Total Debt | 1.28 M | 5.32 B |
| Debt To Equity | 0.50 % | 48.70 % |
| Current Ratio | 16.24 X | 2.16 X |
| Book Value Per Share | 1.70 X | 1.93 K |
| Cash Flow From Operations | (68.31 M) | 971.22 M |
| Earnings Per Share | (2.35) X | 3.12 X |
| Target Price | 24.0 | |
| Number Of Employees | 14 | 18.84 K |
| Beta | 1.86 | -0.15 |
| Market Capitalization | 81.93 M | 19.03 B |
| Total Asset | 135.98 M | 29.47 B |
| Working Capital | 38 M | 1.48 B |
| Current Asset | 48 M | 9.34 B |
| Current Liabilities | 10 M | 7.9 B |
| Z Score | 38.4 | 8.72 |
| Net Asset | 135.98 M |
PCI Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as PCI . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About PCI Biotech Buy or Sell Advice
When is the right time to buy or sell PCI Biotech Holding? Buying financial instruments such as PCI Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having PCI Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials Thematic Idea Now
Financials
Companies that provide financial services to business or retail customers. The Financials theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out PCI Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for PCI Stock analysis
When running PCI Biotech's price analysis, check to measure PCI Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PCI Biotech is operating at the current time. Most of PCI Biotech's value examination focuses on studying past and present price action to predict the probability of PCI Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PCI Biotech's price. Additionally, you may evaluate how the addition of PCI Biotech to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |